Q3 EARNINGS: bioMérieux gets warning letter; Intuitive recovery continues; Thermo lowers guidance
This article was originally published in Clinica
bioMérieux’s third quarter was “broadly in line” with expectations, according to Jefferies analyst Peter Welford. Q3 sales of €412m ($523m) grew 6% year-on-year, with 2.3% organic growth similar to his prediction of 2.6%, but “shy of +3.1% consensus.”
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.